Afatinib free base

• CAT Number: I001295
• CAS Number: 439081-18-2 (free base)
• Molecular Formula: C24H25ClFN5O3
• Molecular Weight: 485.94
• Purity: ≥95%
• Synonyms: BIBW-2992; BIBW 2992; BIBW2992. Afatinib free base; trade name: Gilotrif, Tomtovok and Tovok.
• Target: RTK inhibitor
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4°Cfor short term (days to weeks), or -20 °C for long term (months).
• IUPAC Name: (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide
• InChI: InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1
• InChIKey: ULXXDDBFHOBEHA-CWDCEQMOSA-N
• SMILES: O=C(NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@@H]4COCC4)/C=C/CN(C)C

Afatinib Free Base(CAT: I001295) is a potent and irreversible inhibitor of the epidermal growth factor receptor (EGFR) family, including EGFR, HER2, and HER4. Widely used in oncology research, it targets tyrosine kinase activity, disrupting key signaling pathways involved in tumor growth, survival, and metastasis. Afatinib is particularly effective against EGFR mutations, such as exon 19 deletions and L858R mutations, making it a valuable tool for studying non-small cell lung cancer (NSCLC) and other EGFR-driven cancers. With high purity and stability, Afatinib Free Base is suitable for in vitro and in vivo studies, supporting the development of targeted cancer therapies.